Filing Flows › Biotricity (BTCY) › Q4 FY26 › vs Q3 FY26
Biotricity (BTCY) Q4 FY26 vs Q3 FY26 (quarter over quarter)
Biotricity's revenue rose $263K (+7%) from $4.0M in Q3 FY26 to $4.3M in Q4 FY26. The biggest changes: Technology Fees +$285K (+8%); Device Sales −$22K (-6%).
Biotricity, Q4 FY26: revenue $4.3M (+15% year over year), operating margin 16.3%, net loss $324K, operating cash flow −$21K. The chart draws each line against Q3 FY26, the increases inside each band.
Every line
| Line | Q4 FY26 | Q3 FY26 | Change | % |
|---|---|---|---|---|
| Technology Fees | $3.9M | $3.6M | $285K | +8% |
| Device Sales | $329K | $351K | −$22K | -6% |
| Revenue | $4.3M | $4.0M | $263K | +7% |
| Net loss | $324K | $717K | −$393K | -55% |
| Costs & expenses | $4.6M | $4.7M | −$130K | -3% |
| Operating costs | $3.6M | $3.5M | $9K | +0.3% |
| Interest & other, net | $1.0M | $1.2M | −$139K | -12% |
| Cost of revenue | $852K | $736K | $115K | +16% |
| Research & development | $842K | $624K | $218K | +35% |
| SG&A | $1.9M | $2.2M | −$324K | -15% |
| Operating cash sources | $324K | $717K | −$393K | -55% |
| Depreciation | $1K | $1K | $0 | 0% |
| Share-based compensation | $8K | $6K | $2K | +28% |
| Working capital & other | $294K | −$31K | $325K | — |
| Cash used in operations | $21K | $740K | −$719K | -97% |
| Net loss absorbed | $324K | $717K | −$393K | -55% |
Questions
How much did Biotricity's revenue grow quarter over quarter in Q4 FY26?
Biotricity's revenue rose $263K (+7%) from $4.0M in Q3 FY26 to $4.3M in Q4 FY26.
What drove Biotricity's revenue change in Q4 FY26?
Technology Fees +$285K (+8%); Device Sales −$22K (-6%).